IKS03 Shows Early Activity in Relapsed B Cell Lymphoma
Iksuda disclosed first Phase 1 dose-escalation data for CD19-directed prodrug ADC IKS03 on November 5. Nine of 17 efficacy-evaluable relapsed or refractory B-cell lymphoma patients responded, but heterogeneous histologies, an evaluability restriction and small…
